![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/RPGLIFE.png)
Share the post "RPG Life Sciences ‘s Q3 2024-25 Latest News: Profit Up by 32.01% Year-on-Year"
Highlights
🔹 The presented financial data is Standalone to provide a comprehensive overview of the company performance. 🔹 Sales over the Year and quarter: The company experienced a substantial growth of 12.37 % in the past year, substantial increase in net sales/revenue by 0.29 %. 🔹 Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 72.4 %. Marginal increase in other income during this quarter, up by 113.05%. 🔹 Profit over the Year and quarter: Significant improvement in profitability for RPG Life Sciences Limited. Notable increase of 32.01 % in net profit Year to Year, RPG Life Sciences Limited’s profitability increased by 731.67 % in this quarter. 🔹 EPS over the Year and quarter: EPS increased by 32.00 % Year to Year. EPS increased by 731.5 % in previous quarter. Positive impact on shareholders.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 153.7 Cr | Rs. 172.21 Cr | Rs. 172.71 Cr | + 0.29 % | + 12.37 % |
| Expenses | Rs. 115.8 Cr | Rs. 126.28 Cr | Rs. 123.55 Cr | -2.16 % | + 6.69 % |
| Operating Profit | Rs. 37.9 Cr | Rs. 45.93 Cr | Rs. 49.16 Cr | + 7.03 % | + 29.71 % |
| OPM % | 24.66 % | 26.67 % | 28.46 % | + 1.79 % | + 3.8 % |
| Other Income | Rs. 1.92 Cr | Rs. -25.36 Cr | Rs. 3.31 Cr | + 113.05 % | + 72.4 % |
| Interest | Rs. 0.14 Cr | Rs. 0.17 Cr | Rs. 0.12 Cr | -29.41 % | -14.29 % |
| Depreciation | Rs. 4.14 Cr | Rs. 5.31 Cr | Rs. 5.46 Cr | + 2.82 % | + 31.88 % |
| Profit before tax | Rs. 35.54 Cr | Rs. 15.09 Cr | Rs. 46.89 Cr | + 210.74 % | + 31.94 % |
| Tax % | 25.55 % | 72.17 % | 25.51 % | -46.66 % | -0.04 % |
| Net Profit | Rs. 26.46 Cr | Rs. 4.2 Cr | Rs. 34.93 Cr | + 731.67 % | + 32.01 % |
| EPS in Rs | Rs. 16 | Rs. 2.54 | Rs. 21.12 | + 731.5 % | + 32 % |
Today, we’re looking at RPG Life Sciences Limited’s financial performance for the Q3(Dec 2024-25).Starting with the top line, the company reported a robust year-over-year sales growth of 12.37 %. However, it did see a marginal increase of 0.29 % from the previous quarter. Expenses decreased slightly by -2.16 % quarter-on-quarter, aligning with the annual rise of 6.69 %. Operating profit, while up 29.71 % compared to last year, faced a quarter-on-quarter increase of 7.03 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 3.8 %, but an expansion of 1.79 % sequentially. Other income rose by 113.05 % compared to the last quarter, despite an annual growth of 72.4 %. Interest expenses dropped significantly by -29.41 % from the previous quarter, yet the year-over-year decrease remains at a moderate -14.29 %. Depreciation costs climbed by 2.82 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 31.88 %. Profit before tax grew annually by 31.94 % but saw an increase from the preceding quarter by 210.74 %.
Tax expenses as a percentage of profits decreased slightly by -0.04 % compared to last year, with a more notable quarter-on-quarter decrease of -46.66 %. Net profit rose by 32.01 % year-on-year but experienced a 731.67 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 32 % but a quarterly rise of 731.5 %. In summary, RPG Life Sciences Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 153.7 Cr | Rs. 172.21 Cr | Rs. 172.71 Cr | + 0.29 % | + 12.37 % |
| Expenses | Rs. 115.8 Cr | Rs. 126.28 Cr | Rs. 123.55 Cr | -2.16 % | + 6.69 % |
| Operating Profit | Rs. 37.9 Cr | Rs. 45.93 Cr | Rs. 49.16 Cr | + 7.03 % | + 29.71 % |
| Net Profit | Rs. 26.46 Cr | Rs. 4.2 Cr | Rs. 34.93 Cr | + 731.67 % | + 32.01 % |
| EPS in Rs | Rs. 16 | Rs. 2.54 | Rs. 21.12 | + 731.5 % | + 32 % |
In reviewing RPG Life Sciences Limited’s 2024-25(Q3) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 12.37 % year-on-year growth, however, there was a minor increase of 0.29 % from the previous quarter. Expenses rose by 6.69 % compared to the previous year, with a decrease of -2.16 % quarter-on-quarter. Operating Profit surged by 29.71 % annually, and saw a 7.03 % increase from the last quarter.
Net Profit showed yearly increase of 32.01 %, and experienced a 731.67 % increase from the previous quarter. Earnings Per Share (EPS) rose by 32 % annually, however rose by 731.5 % compared to the last quarter. In essence, while RPG Life Sciences Limited exhibits strong annual growth indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.
![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/AKSPINTEX.png)
![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/ICSL.png)